DNA synthesis now requires federal screening—Commerce Department decides what's too dangerous to sel

What it does

This bill requires companies that synthesize and sell DNA/RNA sequences or sell DNA synthesis equipment to verify buyer identity, establish the intended use, screen sequences against a government-maintained list of high-risk sequences, refuse sales of dangerous sequences, report suspicious buyers to the Commerce Department, and maintain records for 5 years. The Commerce Secretary will publish a list of sequences deemed high-risk to national security or public safety, issue guidance on compliance, and enforce violations with civil penalties up to $750,000 per violation.

Why we flagged it

The bill establishes a mandatory federal screening and reporting regime for nucleic acid synthesis, replacing voluntary industry guidelines with enforceable compliance requirements. It is fundamentally a regulatory expansion in the biosecurity domain, not a deregulation or industry carve-out.

What the text implies

• The Commerce Secretary's discretion to define 'covered sequences' and determine what poses 'unacceptable risk' is broad and not subject to judicial review standards specified in the bill; future administrations could expand the list dramatically.
• Benchtop synthesizer manufacturers face compliance burden even if they do not directly sell sequences, potentially raising barriers to entry for smaller biotech firms and concentrating market power among larger players.
• The bill preempts state and local biosecurity rules, centralizing authority in Commerce; states cannot impose stricter screening even if they believe federal standards are insufficient.
• Trade secret protection for submissions to the Secretary (subsection (f)(3)(C)) may shield industry from public scrutiny of which sequences are flagged and why, reducing transparency of biosecurity decisions.
• The 'covered process' (60-day public comment) is required for guidance but not for the Secretary's initial determination of covered sequences, creating an asymmetry: the list itself may be issued with less public input than the rules for compliance.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain protection against misuse of synthetic biology for bioweapons or dangerous pathogens through mandatory screening and federal oversight. The bill does not restrict citizens' access to legitimate sequences or medical treatments; it restricts only high-risk sequences identified by the government. The 30-day cure period and guidance-based enforcement reduce arbitrary harm to legitimate businesses.

Who stands to gain

• Large nucleic acid synthesis companies (compliance infrastructure investment, market consolidation)
• Compliance and audit service providers (third-party certifications, independent assessments)
• Biosecurity consulting firms

Named in the bill

Secretary of Commerce, Office of the Secretary (Commerce Department), House Committee on Energy and Commerce, Senate Committee on Commerce, Science, and Transportation, Nucleic acid synthesis companies, Benchtop nucleic acid synthesizer manufacturers, Federal agencies (national security, public health)

Where it stands

1 cosponsor: 1 Democrats.

• Aug 31, 2026 — Introduced · Congress.gov: “Introduced in House”
• Aug 31, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.